We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » IMDRF Proposed Document Sets QMS Standards for Device Software

IMDRF Proposed Document Sets QMS Standards for Device Software

April 10, 2015

The International Medical Device Regulators Forum has issued a proposed document explaining how to use quality management systems to regulate software as a medical device.

According to the document developed by IMDRF’s SaMD Working Group, effective QMS should include:

  • A governance structure that provides leadership, accountability, and sufficient resources to ensure SaMD safety, effectiveness and performance;
  • A scalable set of quality processes that apply across the SaMD lifecycle; and
  • A set of key lifecycle activities scalable to the type of SaMD and the size of the organization.

The governance structure should include periodic internal audits of the QMS process, the document says. In addition, management should review verification results to ensure the QMS is suitable, adequate and effective, adjusting it as necessary. The managers should also ensure any staffers working on SaMD projects are properly trained. Maintenance of networks and other work-from-home tools may become more important as offices become more virtual, the guidance says.

The group recommends that SaMD manufacturers monitor potential patient risks throughout the software development process. This should include consideration of user-based risks, such as whether the software could be used by elderly patients, as well as device-based risks, such as whether the software could be used safely on a small smartphone screen. Firms should also consider whether the SaMD will be safe if used in a noisy or distracting environment and what cybersecurity risks the software presents.

In terms of control, IMDRF suggests SaMD developers “align document complexity with organizational maturity” — that is, a small company may not need recordkeeping procedures that are as elaborate as those used by a larger company.

The working group suggests manufacturers design their QMS policy to comply with international standards ISO 13485:2003 on medical devices and ISO 12207:2008 on software development.

View the proposed document at www.fdanews.com/04-13-15-software.pdf. — Elizabeth Orr

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • AstraZeneca

    AstraZeneca Withdraws Imfinzi’s Bladder Cancer Indication

  • CE mark

    Cue Health’s COVID-19 Test Receives CE Mark

  • Sanofi-Regeneron_Logos.png

    Sanofi’s and Regeneron’s Libtayo Wins FDA Approval for NSCLC

  • PerkinElmer logo

    PerkinElmer’s Rapid Point-of-Care COVID-19 Test Cleared in Europe

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing